Health

India’s corneal blindness problem

Context: India is facing an acute shortage of corneas required for transplantation, whereas the cases of corneal blindness in the country are on the rise. 

Corneal Blindness in India

  • Prevalence: Corneal blindness, a leading cause of vision impairment in India, with the country seeing an estimated 20,000 to 25,000 new cases every year.
  • Corneal blindness is vision loss due to damage or scarring of the cornea (the eye's transparent outer layer).
    • Reasons include- Infectious diseases like keratitis, eye trauma, injuries, congenital conditions and deficiencies like vitamin-A.
    • Without timely treatment, it can lead to irreversible blindness.
  • Annual Requirement: Approximately 1,00,000 corneal transplants.
  • Availability: Only 30% of corneal transplants demand is met. 
  • Infrastructure Deficit:
    • India has only 12–14 high-functioning eye banks against the required 50 facilities.
    • Shortage of skilled corneal surgeons with a current need for 500 active specialists.
eye anatomy diagram

Policy Proposals: Presumed Consent vs. Required Request:

  • The Ministry of Health is proposing a policy to allow corneal retrieval from deceased patients without prior family consent, aiming to address the shortage. 
  • It will require a ‘presumed consent’ amendment to the Transplantation of Human Organs and Tissues Act (THOTA), 1994 to allow cornea retrieval from all eligible deaths in hospitals.

1. Presumed Consent:

  • Definition: All deceased individuals are treated as donors unless they have explicitly opted out. 
  • Advantages: Quicker organ-retrieval, the process is simplified by by-passing the requirement of consent from the next-of-kin. (Corneas need to be retrieved within eight to 10 hours after death)
  • Issues: Undermines public trust due to lack of explicit consent. 

2. Required Request:

  • Definition: Seeking consent explicitly from the next-of-kin of the deceased person even if a presumed consent law exists. 
  • Advantages: Builds trust between donors, recipients and the healthcare system. 
  • Challenges: Time-consuming and requires counselling at hospitals. 

India’s Hospital Cornea Retrieval Programme (HCRP):

  • India has a successful model of ‘required request’ corneal donation: a hospital cornea retrieval programme (HCRP).
  • In an HCRP, a grief counsellor approaches the kin of the deceased and initiates a conversation, gently motivating them to consider a donation. The donation is processed only after receiving explicit consent from the kin.
    • Of the 1,40,000 corneas harvested by the Ramayamma International Eye Bank in Hyderabad, over 70% have come from HCRP. 

Way Forward

  • Programs focusing on eye health education and nutritional support, particularly with Vitamin-A supplementation for vulnerable populations.
  • Widespread educational campaigns using media and community events to inform the public about the significance of eye donation, the processes involved, and its positive impact.
  • Building high-functioning eye banks, training corneal surgeons and building specialised units for grief-counseling in general hospitals. 
  • Enhance collaboration between public health bodies, NGOs, and private healthcare providers.

It is therefore possible for India to eliminate avoidable corneal vision loss by investing in a consent-driven donation paradigm, 50 high-functioning eye banks, and by activating 500 corneal surgeons. 

Gaucher’s disease

Context: In 2014, the Delhi High Court, in a ruling, allowed for free enzyme replacement therapy for a rare condition (Gaucher’s disease), to a seven-year-old child.

More information from the news: 

  • On October 4, 2024, the Delhi High Court once again extended its support to those suffering from rare diseases, as it had done in the 2014 verdict.
  • The court also issued several directives, including a call for the Central Government to establish a fund of Rs 974 crores dedicated to the treatment and support of over 100 individuals affected by rare diseases across the nation.
  • The court cited the 2014 case, Mohd Ahmed (Minor) v. Union of India, to reaffirm that the ‘right to health is part of the right to life (Article 21).’
Gaucher’s disease (GD)

About Gaucher’s disease

  • Gaucher’s Disease (GD) is a rare genetic disorder caused by the deficiency of an enzyme that breaks down fatty substances called lipids. Lipids start to build up in certain organs such as spleen and liver.

There are 3 types of Gaucher’s disease:

  1. Type 1: This is the most common type of Gaucher disease. It affects about 90% of people with the disease. In type 1, the patient does not have enough platelets in blood. This can make him/her bruise easily and feel very tired (fatigued). The symptoms can start at any age and the patient has an enlarged liver or spleen. It may also include kidney, lung, or skeletal problems.
  2. Type 2: This form of the disease affects babies by age 3 to 6 months. It is fatal. In most cases children don’t live beyond 2 years old.
  3. Type 3: Symptoms include skeletal problems, eye movement disorders, seizures that become more obvious over time, blood disorders, breathing problems, and liver and spleen enlargement.

Causes of Gaucher’s disease: 

  • Gaucher disease is passed down from parents to children (is inherited). It is caused by a problem with the GBA gene.
  • It is an autosomal recessive disorder. This means that each parent must pass along an abnormal GBA gene for their child to get Gaucher.
  • Parents may have only 1 GBA gene and, therefore, not show any signs of the disease, but be carriers of the disease.

Note: 

  • The GBA gene provides instructions for making an enzyme called beta glucocerebrosidase.
  • This enzyme is active in lysosomes, which are structures inside cells that act as recycling centres.
  • Lysosomes use digestive enzymes to break down toxic substances, digest bacteria that invade the cell, and recycle worn-out cell components.
  • Based on these functions, enzymes in the lysosome are sometimes called housekeeping enzymes.
  • Beta-glucocerebrosidase is a housekeeping enzyme that helps break down a large molecule called glucocerebroside into a sugar (glucose) and a simpler fat molecule (ceramide).
  • More than 380 mutations in the GBA gene have been identified in people with Gaucher disease. 
  • The mutations occur in both copies of the gene in each cell.
  • Most of the GBA gene mutations responsible for Gaucher disease change single protein building blocks (amino acids) in beta glucocerebrosidase, altering the structure of the enzyme and preventing it from working normally.
  • Other mutations delete or insert genetic material in the GBA gene or lead to the production of an abnormally short, nonfunctional version of the enzyme.
  • Mutations in the GBA gene greatly reduce or eliminate the activity of beta glucocerebrosidase in cells.
  • As a result, glucocerebroside is not broken down properly.
  • This molecule and related substances can build up in white blood cells called macrophages in the spleen, liver, bone marrow, and other organs.
  • The abnormal accumulation and storage of these substances damages tissues and organs, causing the characteristic features of Gaucher disease.

Symptoms of Gaucher’s disease can include:

  • Enlarged spleen; Enlarged liver; Eye movement disorders; Yellow spots in the eyes; Not having enough healthy red blood cells (anemia); Extreme tiredness (fatigue); Bruising; Lung problems; Seizures. 

Treatment

  • There is no cure for Gaucher disease. But treatment can help control the symptoms. 
  • The treatment will depend on the type of Gaucher disease. 
  • Treatment may include:
    • Enzyme replacement therapy, which is effective for types 1 and 3
    • Medicines
    • Regular physical exams and bone density screening to check the disease
    • Bone marrow transplant
    • Surgery to remove all or part of the spleen
    • Joint replacement surgery
    • Blood transfusions

Note: 

  • Enzyme replacement therapy is typically used to replace a missing or deficient enzyme in a person with an inherited enzyme deficiency syndrome.
  • The missing enzyme is replaced by infusions of an enzyme that is purified from human or animal tissue or blood or produced by novel recombinant techniques.
  • Typically, the enzyme is modified to allow for a longer half-life, more potent activity, resistance to degradation or targeting a specific organ, tissue or cell type.
  • The first successful enzyme replacement therapies were for alpha-1-antitrypsin (A1AT) deficiency using plasma derived purified human A1AT. 
  • A second form of successful enzyme replacement therapy was established for Gaucher disease.

Food adulteration

Context: The Food Safety and Standards Authority of India (FSSAI) has issued a show-cause notice to a Tamil Nadu-based firm, which supplied ghee to the Tirupati temple in Andhra Pradesh, for allegedly providing substandard product to the temple.

About Food adulteration

About Food adulteration

It is the intentional or unintentional addition of substances to food that can make it harmful to consume. These substances, known as adulterants, can be added to increase the quantity, reduce the cost, or improve the appearance of food.

Common types of adulterants :

  • Milk is often adulterated with water, detergent, fat, and even urea.
  • Preservatives such as nitrites (used in cured meats)and benzoates (used in soft drinks and pickles), lead to digestive issues and long-term health problems.
  • Tea leaves are commonly mixed with similarly colored leaves, some of which are inedible.
  • Cornstarch, sawdust, and flour are used as fillers in spices.
  • Antibiotics and hormones such as estrogen and testosterone in meat and poultry to promote growth, but excessive consumption can lead to antibiotic resistance and hormone imbalances.
  • Khoya is adulterated with paper, refined oil, and skimmed milk powder.
  • Pesticides (like DDT and organophosphates) in fruits and vegetables, heavy metals like lead and mercury in seafood, and industrial pollutants in food packaging.
  • Foreign substances such as insects, dirt, or other foreign substances can accidentally contaminate food during processing or storage.
  • Arhar dal is usually adulterated with metanil yellow.

Reason behind ghee adulteration: 

  • High price of milk fat: Milk-derived fats from cow and buffalo milk cost around Rs 460-470 per kg, with ghee production and packaging raising the price to Rs 485-495 per kg. This high cost incentivizes adulteration to cut production expenses.
  • Price differential between milk and vegetable fats: Vegetable fats, such as refined palm, soybean, sunflower, and rapeseed oils, are significantly cheaper, ranging from Rs 120-150 per kg. The vast price difference between milk fats and vegetable fats encourages manufacturers to mix the latter into ghee to increase profits.
  • Scarcity of milk fat: Milk fat is relatively scarce, as dairies prioritize selling liquid milk and producing other products like curd and lassi . Only limited availability of milk is available for the manufacture for production of ghee, further increases its value and drives adulteration.
  • Profit motive of dairies: Large dairy cooperatives and private players prefer selling ghee in retail consumer packs rather than in bulk, as it fetches higher profits. Some dairies also use milk fat for ice cream production, which offers better returns. This reluctance to sell ghee in bulk pushes organizations to seek cheaper, often adulterated, alternatives.
  • Lower demand and competition: Sales of ghee from companies like Patanjali have decreased significantly in recent years, putting additional pressure on manufacturers to cut costs, potentially through adulteration.

Laws deal with food adulteration:

  • Under Indian Constitution, the adulteration of foodstuffs and other items falls in the Concurrent List.
    • Food Safety and Standards Act, 2006: It is a comprehensive legislation dealing with various aspects with respect to the regulation of food safety.
    • Food Safety and Standard Authority of India (FSSAI) is established under Section 4 of the Act to supervises and regulates food safety and standards.
    • It prohibits any person to operate any food business without a license.
    • The law prohibits producing, selling, and distributing contaminated or counterfeited foods.
    • The Act also imposes a penalty for the possession of adulterant.
  • The Bharatiya Nyaya Sanhita (BNS): Impose penalties, including imprisonment and fines, for food adulteration, with stricter punishments for hazardous food practices.

Read also: About FSSAI

State Food Safety Index 2024

Context: Kerala, Tamil Nadu, and Jammu & Kashmir were ranked as the top three performers on the State Food Safety Index 2024.

Key findings of State Food Safety Index 2024: 

image 6
  • Kerala has, for the second time in a row, topped the sixth State Food Safety Index (SFSI) 2024 and has achieved more than 100 per cent of its inspections target in FY24, improved its food-testing infrastructure and organised special drives to increase the number of license-holders and registrations, among other achievements. 
  • Tamil Nadu has got a “significant number of full-time designated food safety officers.
  • Jammu and Kashmir got third position in the Index while Gujarat secured fourth position in the Index.
  • Nagaland was given special acknowledgement among the northeastern states as the index said that the hilly state showed overall progress in improving the food safety ecosystem compared to the previous year.
  • Eat Right campaign, the Pradhan Mantri Garib Kalyan Yojana, and the promotion of millets as important initiatives the centre took to ensure safe and good food.

About State Food Safety Index (SFSI):

  • Released by: Food Safety and Standards Authority of India (FSSAI).
  • Released on: June 7 on the occasion of World Food Safety Day.
  • 1st report: Since 2019.
  • Parameters: Human resources and institutional data , compliance, food testing infrastructure, training and capacity building, and consumer empowerment. In the 2023 index, a new parameter ‘Improvement in SFSI Rank’ was added
  • Objective: To foster healthy competition and catalyse positive change in the food safety ecosystem throughout the country, ultimately ensuring the provision of safe and wholesome food to all residents.

About FSSAI:

Body: Statutory body has been established under Food Safety and Standards , 2006. It works as an independent authority and attained a special status. The FSS Act took 7 older acts into one umbrella.

  • Prevention of Food Adulteration Act, 1954. 
  • Fruit Products Order, 1955 
  • Meat Food Products Order, 1973
  • Vegetable Oil Products (Control) Order, 1947  
  • Edible Oils Packaging (Regulation) Order 1998  
  • Solvent Extracted Oil, De- Oiled Meal and Edible Flour (Control) Order, 1967  
  • Milk and Milk Products Order, 1992 
  • Nodal ministry: Ministry of Health & Family Welfare, is the Administrative Ministry for the implementation. 
  • Headed by: Non-executive chairperson, appointed by the Central Government, either holding or has held the position of not below the rank of Secretary.
  • Objective: To establish a single reference point for all matters relating to food safety and standards, by moving from multi- level, multi- departmental control to a single line of command. 
  • Function: 
    • Framing of regulations to lay down food safety standards
    • Laying down guidelines for accreditation of laboratories for food testing
    • Providing scientific advice and technical support to the Central Government
    • Contributing to the development of international technical standards in food
    • Collecting and collating data regarding food consumption, contamination, emerging risks, etc.
    • Disseminating information and promoting awareness about food safety and nutrition in India.

Expansion of Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY) for Senior Citizens

More about news:

  • Approval by Union Cabinet (September 2024):
    • Health Coverage Expansion: As per the Union Cabinet announcement in September 2024, the government extended health coverage under AB PM-JAY to all senior citizens aged 70 and above, benefitting around 6 crore senior citizens and 4.5 crore families.
    • Insurance Coverage: Each senior citizen will receive health insurance cover worth ₹5 lakh annually under this new provision.
    • Distinct Health Cards: Eligible citizens will receive separate AB PM-JAY health cards for easy identification and service delivery.
  • Top-Up for Existing Beneficiaries:
    • Senior citizens already covered under AB PM-JAY will receive an additional top-up of ₹5 lakh, providing exclusive health coverage for themselves.
  • Choice of Scheme: Senior citizens already benefiting from other schemes like Central Government Health Scheme (CGHS), Ex-Servicemen Contributory Health Scheme (ECHS), and Ayushman CAPF will have the flexibility to choose between these schemes or AB PM-JAY.

About Ayushman Bharat : It is a flagship scheme of Government of India, was launched as recommended by the National Health Policy 2017, to achieve the vision of Universal Health Coverage (UHC). This initiative has been designed to meet Sustainable Development Goals (SDGs) and its underlining commitment, which is to "leave no one behind."

  • Ayushman Bharat adopts a continuum of care approach, comprising two inter-related components, which are –
    • Health and Wellness Centers (HWCs): In February 2018, the Government of India announced the creation of 1,50,000 Health and Wellness Centres (HWCs) by transforming the existing Sub Centres and Primary Health Centres. These centres are to deliver Comprehensive Primary Health Care (CPHC) bringing healthcare closer to the homes of people. They cover both, maternal and child health services and non-communicable diseases, including free essential drugs and diagnostic services.
    • Pradhan Mantri Jan Arogya Yojana (PM-JAY): The second component under Ayushman Bharat is PM-JAY, the largest health assurance scheme in the world, which aims at providing a health cover of Rs. 5 lakhs per family per year for secondary and tertiary care hospitalization across public and private empanelled hospitals in India.
Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY) for Senior Citizens

Significance of Ayushman Bharat

(i) The increasing life expectancy rate over 68.3 years has improved the quality of health care in India.

(ii) Health care is an essential factor, along with other variants like income, hygiene, and nutrition.

(iii) According to the World Health Organization, every country must invest at least 4% of the Gross Domestic Product (GDP) on their health.

(iv) The out-of-pocket expenditure on healthcare is 40% in India.

(v) The Government Scheme not only covers for expensive treatments but also provides quality services to all the people eligible under the plan.

Provisions of Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY):

1. Largest Public Health Assurance Scheme: The scheme is the world’s largest publicly funded health assurance program.

  • Launched in 2018, the Ayushman Bharat scheme covers 55 crore individuals or 12.34 crore families, offering health insurance worth ₹5 lakh per year for secondary and tertiary care hospitalisation.

2. Coverage of Pre and Post-Hospitalization Costs: Costs of diagnostics and medicines are covered for:

  • Up to 3 days before hospitalization (pre-hospitalization).
  • 15 days after hospitalization (post-hospitalization).
  • All pre-existing medical conditions are also covered.

3. Ayushman Card: The Ayushman Card acts like a pre-paid card worth ₹5 lakh.

  • Can be used to avail free treatment at more than 27,000 empanelled hospitals across India.
  • Every hospital must have Pradhan Mantri Arogya Mitras (PMAMs) to assist the beneficiaries.

4. Interstate Portability: The scheme offers interstate portability, allowing beneficiaries to access treatment at empanelled hospitals across different states.

5. Aadhaar-Based Authentication: Aadhaar-based authentication is required for:

  • Card creation.
  • Registration for treatment under the scheme.

6. Administration by the National Health Authority (NHA): The scheme is administered by the National Health Authority (NHA) under the Ministry of Health and Family Welfare.

  • NHA has a governing board with representatives from the central government, domain experts, and state authorities.
  • Post-Discharge Follow-up:
    • NHA’s call center contacts beneficiaries 48 hours post-discharge to assess treatment quality.
    • A second follow-up call is made 15 days post-discharge to check the patient’s prognosis.

7. Inclusivity: PM-JAY is an inclusive scheme, covering transgender individuals among its beneficiaries.

  • 50 special packages were designed for transgender healthcare needs, including Sex Reassignment Surgery (SRS).

8. Anti-Fraud Mechanism: The National Anti-Fraud Unit (NAFU) designs, implements, and oversees anti-fraud initiatives within the scheme.

  • Anti-Fraud Units also operate at the state level to prevent misuse and fraud in the healthcare system.

Achievements of Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY):

1. Nudging of State Governments: The scheme has encouraged states and Union Territories, responsible for public health under India's federal structure, to expand healthcare coverage to more beneficiaries.

  • National Sample Survey Organization (NSSO) 71st round: It was found that 85.9% of rural and 82% of urban households lacked healthcare insurance. PM-JAY specifically targets deprived and poor families, addressing this critical gap.

2. Effective fiscal management: AB-PMJAY has reduced Out-of-Pocket Expenditure (OOPE), which has been a significant financial burden for Indian households.

  • Over 17% of Indians previously spent more than 10% of their household budget on healthcare, leading many into debt. The scheme mitigates these financial risks by providing coverage for secondary and tertiary care.

3. Bridge the gap: PM-JAY has effectively connected healthcare providers with service users by uniting them through government channels, thereby addressing the shortfall in access to healthcare services for marginalized populations.

4. Spirit of Inclusiveness:  The scheme promotes inclusivity, with 48% of treatments being availed by women, and also covers transgender individuals.

  • Beneficiaries can access services even if they do not possess an Ayushman card at the time of treatment, ensuring no one is left out.

5. Regularisation of process: In order to engage private healthcare providers effectively, Health Benefit Packages (HBPs), covering in-patient treatment, have been revised five times in the last five years to stay relevant and comprehensive.

6. Early Claim settlement: To ensure smooth and timely financial management, efforts are being made to settle claims within a 15-day standard. States like Uttarakhand have managed to reduce the settlement time to under seven days, setting an example for others.

7. Reward to Hospitals: To encourage trustworthy and efficient hospital service, hospitals with a good record receive 50% of the claim amount as an upfront payment immediately after submitting their claims, without the need for adjudication.

8. Interoperability: The scheme is particularly beneficial for migrants, providing interoperability across states and ensuring that the poor and marginalized can access healthcare services even when they move across borders. This has proven vital in emergencies.

9. Effective Monitoring: The end-to-end digital service delivery system eliminates bias, ensuring transparency. The National Health Authority (NHA) monitors the scheme's implementation through internal checks and a public dashboard, enabling real-time tracking.

10. Fraud management: The establishment of institutions like the National Anti-Fraud Unit (NAFU) has significantly reduced fraud in the registration, verification, and insurance claims processes, ensuring accountability and integrity within the system.

11. Use of technology: Leveraging Artificial Intelligence (AI) and Machine Learning (ML), the NHA uses advanced technology to detect suspicious transactions and potential fraud, ensuring efficient monitoring and reducing misuse of the scheme.

Issues 

1. Exclusion Error: One of the most significant challenges is the Socio-Economic Caste Census (SECC) data, which has been criticized for non-transparent methods of data collection and outdated population figures.

  • These errors can lead to eligible beneficiaries being left out, and hence, there is a need to update and improve the estimates for better targeting.

2. Asymmetric Federalism: Several states have increased the coverage of the scheme via state schemes. This entails increased expenditure by states which choose to expand coverage, such as Kerala. However, this may be particularly hard for cash-strapped states like Bihar which depend on Union government funding more than their own resources.

3. Ghost Beneficiaries: Unrelated ineligible beneficiaries are admitted based on forging a relationship with the head of the beneficiary family. The challenge that lies ahead for National Health Authority is to strengthen artificial intelligence to pick up all such instances of fraud.

4. Future Fiscal Burden: As insurance coverage grows, there is a possibility of a rise in hospitalization rates, leading to increased claim ratios and higher premiums, which may strain government finances.

  • Insurers, needing to run a profitable business, may demand higher premiums, creating fiscal stress on the program.

5. Infrastructural and man-power issues:  Public health infrastructure faces severe deficiencies:

  • 10% of Primary Health Centers (PHCs) lack doctors.
  • 56% of sub-centers (SCs) lack staff washrooms, 73% lack separate washrooms, and 36% of PHCs do not have gender-segregated facilities.

These infrastructural gaps undermine the scheme's effectiveness.

6. Compliance Burden: In rural India, beneficiaries face a significant compliance burden due to long distances to hospitals, which makes access to care difficult. This often results in a lower than expected usage of health services.

7. Double Charging: Publicly Funded Health Insurance Schemes (PFHIS) are prone to double charging, where the hospital makes the patient pay for some or all services/medicines/diagnostics which are covered under the PFHI and also claim the reimbursement from the PFHI.

8. Information Asymmetry: There is a lack of awareness among beneficiaries about their entitlements under the scheme.

  • The hierarchical structure of the healthcare system and the complexity of the scheme exacerbate this issue, leading to low utilization of the available benefits.

9. Outpatient Care: AB-PMJAY does not cover outpatient care, which constitutes between 40% and 80% of Out-of-Pocket Health Expenditure (OOPHE). This is a significant gap, as outpatient care is a major contributor to rising health expenses.

10. Upcoding: Upcoding is the practice of fraudulent medical billing in which the bill for a medical service is more expensive than it should have been based on the service that was performed.

11. Cost: The rates provided by PM-JAY serve as guidelines and have not been strictly followed by states, which has either kept big hospitals at bay or resulted in disparities in service costs across states.

12. Empanelment: Empaneling hospitals in remote areas, such as in the northeast and Leh, has been difficult, creating significant gaps in healthcare access for people living in these regions.

13. Inequity in access: There is inequity in access to healthcare, especially for the poor. Many patients suffering from serious illnesses find that their conditions are not listed among the medical packages covered under AB-PMJAY, leaving them without adequate support.

14. Implementation: The scheme faces several implementation issues:

  • Improper procedures for empanelment and cost fixation mechanisms.
  • Inordinate delays in reimbursement to hospitals.
  • Lack of standardization in services across hospitals, with the National Accreditation Board for Hospitals (NABH) certification covering only some hospitals.
  • Budgetary constraints are also a major issue, as the AB budget, while substantial, may not be sufficient to cover the growing costs of the scheme. This has resulted in payment backlogs to hospitals, which has led some hospitals to limit the number of patients they accept under the scheme.
  • Beneficiaries often prefer private hospitals over public ones due to perceived better quality care and fewer capacity constraints in private institutions.

15. Low Monitoring and Grievance Redressal: Monitoring of the scheme is suboptimal, with several states yet to form State Health Authorities (SHAs) or establish Anti-Fraud Cells and Claim Review Committees.

  • For example, a CAG report revealed the fraudulent registration of 7.5 lakh beneficiaries under a single phone number.
  • Additionally, the Public Financial Management System (PFMS) guidelines for tracking expenditure flows have not been fully complied with.

16. Parallel Systems and Beneficiary Overlap: Some states operate parallel transaction management systems, leading to the overlap of beneficiaries between Ayushman Bharat and state-specific health schemes. This creates confusion and may result in inefficiencies in service delivery.

Suggestions for improvement

  • Improve the public health sector by dealing with limited resources and creating systems that encourage healthcare providers and patients to support universal health coverage.
  • There is a need to consolidate government healthcare spending and clear payment backlogs owed to hospitals by the government.
  • To realise the scheme’s full potential, the National Health Authority (NHA) along with its counterparts in the states should aim to provide every possible beneficiary with an Ayushman Card.
  • State governments which have not formed the SHAs, Fraud cells etc. should consult and through dialogue the bodies should be constituted to improve the interoperability of the scheme.
  • The issue of upcoding, dead patients availing benefits, double charging should be addressed by reducing information asymmetries and increasing the awareness of the people.
  • Parallel transactions management system creates ambiguities in management and ensuring accountability, states and Centre should come up with a unified and transparent system.
  • Recommendations by Indian Medical Association (IMA):

            i. Government hospitals, which already provide services free of charge, should be excluded from the scope of the scheme. Instead, public hospitals should receive direct funding from the government.

           ii. India should move away from utilizing insurance-based healthcare delivery due to high administrative costs and problematic ties with insurance companies, which often prioritize profits over quality care.

The goal of 'Swasth Bharat' should be to embrace a holistic approach to health, which will naturally progress towards a 'Sampann Bharat' or a prosperous India. To realize this vision, there is a need for effective implementation of this scheme.

Unlocking the Potential of Health Sector Allocations: Key Challenges and Opportunities

Context: The effectiveness of Union Budget allocations for India’s health sector largely depends on State-level factors. Since many health initiatives are implemented as Centrally Sponsored Schemes (CSS), State governments play a vital role in their success by sharing costs and ensuring smooth execution. Two major CSS programs, the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM-ABHIM) and Human Resources for Health and Medical Education (HRHME), aim to bolster India's healthcare infrastructure and workforce, but their success faces multiple hurdles.

Key Initiatives in Health Sector

  1. PM-ABHIM
    • Aims to strengthen health infrastructure, build health and wellness centres (HWCs), block-level public health units (BPHUs), district public health labs (IDPHLs), and critical care hospital blocks (CCHBs).
    • Focuses on improving India’s emergency preparedness, especially for pandemics.
  2. HRHME
    • Focuses on increasing the capacity of medical education by establishing new medical, nursing, and paramedical colleges.
    • Plans to strengthen district hospitals and convert them into medical colleges.
    • Aims to address shortages of medical personnel through increased seats and better training infrastructure.

Key Highlights of the article 

1. Low Fund Utilisation in Key Health Schemes: Despite ambitious goals, fund utilisation in both PM-ABHIM and HRHME has been low, reflecting inefficiencies in budget absorption.

  • PM-ABHIM: In 2022-23, only 29% of the budget estimate was spent. In 2023-24, although the revised estimate increased to 50%, the actual expenditure is expected to be lower.
  • HRHME: Utilisation of funds was around a quarter of the budget estimates in both 2022-23 and 2023-24.

Key Challenges in Fund Utilisation

  1. Dependence on 15th Finance Commission Health Grants
    • Around 60% of PM-ABHIM’s funding is sourced from health grants recommended by the 15th Finance Commission. Only about 45% of these grants were utilised from 2021-22 to 2023-24, partly due to complex execution procedures at the State level.
  2. Integration of Health Programs
    • States are required to merge public health labs from various vertical programs under IDPHLs, necessitating significant planning and reorganisation. This integration has delayed implementation.
  3. Delayed Fund Absorption in Construction Projects
    • Components like BPHUs and CCHBs involve construction, where fund absorption is slowed by rigid procedural requirements and overlapping funding from multiple sources.

2. Shortage of Faculty and Specialists: A major challenge for HRHME is the shortage of teaching faculty and specialists, which affects both new and existing medical institutions. According to a study by the Centre for Social and Economic Progress (CSEP), 

  • Faculty Shortage in AIIMS: There is a 40% shortage in teaching positions across 11 newly created AIIMS.
  • State Medical Colleges: In Uttar Pradesh, 30% of teaching faculty positions in newly established government medical colleges were vacant in 2022.
  • Specialist Shortages in Hospitals: More than a third of sanctioned specialist positions in urban CHCs and two-thirds in rural CHCs were vacant as of March 2022.

3. Fiscal Space Constraints for States: The financial burden of maintaining new health infrastructure will fall on State governments once the central support ends in 2025-26. States will need to plan for additional recurring costs, which may strain their fiscal space.

  • State governments need to create fiscal capacity not only to sustain PM-ABHIM and HRHME infrastructure but also to support other health schemes and initiatives.

Conclusion: For the Union Budget’s health allocations to translate into meaningful health outcomes, the following factors are crucial:

  • Strengthening the fiscal capacity of States to support recurring expenses.
  • Addressing human resource shortages, especially in teaching faculty and specialists.
  • Streamlining public financial management processes to improve fund absorption and scheme execution.

Addressing these challenges will be essential to ensure that capital expenditures in India’s health sector lead to improved infrastructure and better healthcare delivery.

India to roll out new treatment regimen for drug-resistant TB

Context: Tuberculosis (TB) is a silent crisis that impacts the physical as well as mental health of millions of people in India. India needs to scale up investment and formulate new strategies to meet its goal of Tuberculosis eradication by 2025.

Tuberculosis (TB)

  • TB is an airborne communicable disease caused by the bacteria Mycobacterium tuberculosis.
    • Typically, the bacteria grow in the body where oxygen and blood are in high amounts. 
    • As a result, 80% of TB cases are pulmonary which infect the lungs and 20% of cases are extra-pulmonary which infect the brain, uterus, stomach, mouth, kidneys and bones.
  • Mode of transmission: Airborne- through coughing, sneezing or spitting.
  • High-risk groups: People with weak immunity like those infected with HIV, Under-nutrition, Diabetes, Smoking and Alcohol consumption.
Tuberculosis (TB)

Drug-resistant Tuberculosis (DR-TB):

  • DR-TB refers to various forms of TB where the bacteria have developed resistance to at least one of the anti-TB drugs, which makes the infection harder to treat.   

Types of Drug-Resistant TB: There are two main categories:

1. Multidrug-Resistant Tuberculosis (MDR-TB):

  • Resistant to at least isoniazid and rifampicin (the two most powerful first-line drugs).   
  • Treatment is longer, more expensive, and has more side effects.   

2. Extensively Drug-Resistant Tuberculosis (XDR-TB):

  • A severe form of MDR-TB.   
  • Resistant to isoniazid, rifampicin, at least one fluoroquinolone, and at least one of three injectable second-line drugs.
  • Extremely difficult to treat and has a high mortality rate.   

Causes of Drug Resistance:

  • Improper or incomplete treatment: Not taking all prescribed medication or stopping treatment prematurely.    
  • Poor-quality medicines: Counterfeit or substandard drugs.  
  • Overuse of antibiotics: Contributing to the development of drug resistant bacteria. 

​​Present Status of TB:

  • India tops the list of 20 TB high-burden countries in the world. India accounts for 27% of the total TB patients in the world. In 2022, 2.42 million Indians were diagnosed with tuberculosis. 
  • Target for TB elimination:
    • The United Nations’ Sustainable Development Goals has a target to ending the TB epidemic by 2030. 
    • India aims to eliminate TB in the country by 2025.
  • WHO has acknowledged India’s success on two major fronts:
    • In reducing TB incidence by 16% from 2015 to 2022 (close to double the pace at which global TB incidence is declining).
    • In reducing TB mortality by 18% during the same period, keeping in line with the global trend.

Read also: Global Tuberculosis Report 2023

Prevention and Treatment:

  • Prevention:
    • BCG vaccine for children. 
    • Currently no effective vaccine for adults.
  • Diagnosis:
    • Early diagnosis is extremely important in fighting TB. 
    • Widely followed diagnosis methods include- Sputum smear microscopy which studies the phenotype of the pathogen from the sputum sample of infected patients.
  • Treatment: 
    • Strategy: DOTS strategy (Directly Observed Treatment Short Course) is a WHO-recommended cost-effective strategy to reduce the disease burden of TB. 
    • Antibiotics: Administering commonly used antibiotics like rifampin.
  • Challenge: Mycobacterium tuberculosis has developed drug resistance.

Existing challenges associated with TB: 

  • High-prevalence of TB: The reasons include-
    • ​​Lack of widespread awareness about the disease, lack of access to quality care, under-reportion of cases.
      • The National TB Prevalence Survey (in India) found that 64% of people with infectious TB did not seek care. This results in under-reporting of TB incidences and hence, widespread TB prevalence. 
    • Excessive focus on affected patients only, while ignoring the ‘potential’ patient who might be in contact with the patients. 
  • Non-compliance to Follow-up period: Premature treatment cessation fosters the development of drug-resistant strains like multi-drug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB). 
  • Mental Health crisis: TB is associated with a deep stigma, and those affected are still ostracised and mistreated by families, communities, and even the health system. All of this has a significant impact on their mental health. 
  • Gendered issue: There is a significant difference in how males, females and transgenders receive such health care services. Females and transgenders have greater risk of discontinuing treatments, facing greater stigma from society and apathy of healthcare systems. 
  • Re-lapse of TB: The healthcare crisis during the COVID-19 pandemic has reversed the previous gains and increased the TB burden. 

Efforts towards eradicating TB: 

Global initiatives:

  • End TB Strategy: Global strategy developed by WHO that aims to reduce TB deaths by 90% and to cut new cases by 80% by 2030..
  • Global Fund to Fight AIDS, TB and Malaria (2003): Single largest channel of additional money for global TB control.
  • Stop TB Partnership: Global partnership of organisations, governments, and individuals working to eliminate TB advocating political commitment & technical assistance. 

India’s Initiatives:

  • National TB Elimination Programme (NTEP):
    • Adopted in 1997 after WHO declared TB as a global epidemic in 1993. 
    • Previously known as the Revised National Tuberculosis Control Programme or RNTCP.
    • RNTCP focuses on Early Diagnosis and Treatment in accordance with DOTS strategy. 
    • Under RNTCP about 4 lakh DOTS centres have been established so far. Patients are supported with free diagnostics and medicines.

NTEP implements key activities as under:

-State and District Specific Strategic plan for targeted interventions in high-burden areas.
-Provision of free drugs and diagnostics to TB patients including for drug-resistant TB.
-Active TB case-finding campaign in key vulnerable and co-morbid populations.
-Integration with Ayushman Bharat - Health & Wellness Centres to decentralise screening and treatment services closer to the community.
-Private sector engagement including incentives for notification and management of TB cases.
-Scale-up of molecular diagnostic laboratories to sub-district levels.
-Intensified IEC campaigns to reduce stigma, raise community awareness and improve health-seeking behaviour.
-Multi-sectoral response with involvement of line ministries.
-Scale up TB preventive therapy to contacts of pulmonary TB.
-Tracking of notified TB cases through a case-based web-based portal namely Ni-kshay. Nikshay Portal [Ni-Kshay-(Ni=End, Kshay=TB)] is the web enabled patient management system for TB control under the National Tuberculosis Elimination Programme (NTEP).
-Ni-kshay Poshan Yojana for nutritional support to TB patients. It has been implemented from April 2018, wherein 500 rupees per month is being provided to All TB patients towards nutritional support for the duration of their treatment.

  • National Strategic Plan for TB Elimination 2017-2025:
    • Adopted in 2018 in line with the TB Elimination Strategy of the WHO and SDG of the UN. (India has set ambitious targets for reducing TB incidence, prevalence and mortality rates by 2025).
    • Includes 4 strategic pillars: "Detect – Treat – Prevent – Build".
    • Specific targets include:
      • 80% reduction in TB incidence 
      • 90% reduction in TB mortality 
      • 0% patients having catastrophic expenditure due to TB. 
  • Pradhan Mantri TB Mukt Bharat Abhiyan:
    • Launched in September 2022 where the community is encouraged to adopt TB patients and support them.
    • Support can be provided in the form of nutritional support, nutritional supplements, additional investigations, and vocational support for a minimum period of six months or maximum period of up to three years. 
  • Establishment of Centres of Excellence:
    • Facilitates collaboration between Indian Council of Medical Research laboratories and the private sector to strengthen and expand research and development efforts for TB.

 Way Forward:

  • Prioritise TB vaccine trials: Bacille Calmette-Guérin (BCG) vaccine for TB does not adequately protect adolescents and adults who are at the highest risk for developing and spreading TB. Streamline clinical trials for over 15 TB vaccine candidates in the pipeline.
  • Leveraging technology and innovation:
    • Diagnosing TB needs to become more accessible and affordable: E.g.,
      • New innovations such as nasal and tongue swab-based tests for TB can reduce diagnostic delays. E.g., Scaling up Nucleic Acid Amplification Test (NAAT) coverage. 
      • Handheld digital X-ray machines (with artificial intelligence-based software) can offer mobility to test risk-risk individuals in villages.
    • Develop new therapeutic models: Invest more in drug discovery, introduction and development of new therapeutic molecules which have short time-periods.
    • Adoption of AI and digital health solutions for TB diagnosis, adherence and surveillance.  
  • Regulatory frameworks: Need to create regulatory and policy frameworks for strict enforcement of drug control and non-compliance with treatment regimens to tackle antibiotic resistance.
  • Address socio-economic determinants of TB: Multi-sectoral approach is needed like poverty alleviation, improvement in nutritional status, well-ventilated housing and better air quality.
Nucleic Acid Amplification Test (NAAT):Nucleic Acid Amplification Tests (NAATs) are molecular diagnostic tests that detect the presence of specific genetic material (DNA or RNA) from pathogens such as bacteria and viruses. It is a powerful tool for diagnosing a wide range of infections, including, COVID-19, influenza, HIV, hepatitis, tuberculosis etc.

In case of TB, NAAT is used to detect the DNA of Mycobacterium tuberculosis complex (MTBC) in a sputum or other respiratory sample.

AD 4nXdRPqTRZx7RP6ZssfqgcqTE2 BDQ6CinY vq2kRPhIzPlxAjJZqoKdXT51VwwX85cNHHBUIj wKcwxlMGbb7tac3zYbhwYnTH 3F8QicxABc3qE9hYM0tgC0k87 x my4DzCLCYNjkOGbqit6RNBsZmc2fsyECJTqhaRVehziQvEt8SPncWupI?key=kDEVFSpufp5JeAE8Q2Igog

How does NAAT work?

Sample Collection: A sample is collected from the patient, such as a swab from the nose or throat, blood, or urine.

Extraction: The nucleic acid (DNA or RNA) is extracted from the sample.

Amplification: The target nucleic acid sequence is multiplied (amplified) millions of times using specific techniques like Polymerase Chain Reaction (PCR).

Detection: The amplified nucleic acid is detected and identified, confirming the presence of the target organism.

No clinical trial for drugs approved in select nations

Context: The Union government has authorised the exemption of local clinical trials for approval of new drugs under Rule 101 of the New Drugs and Clinical Trial Rules, 2019. 

Major highlights

  • Under the Rule 101 of the New Drugs and Clinical Trial Rules, 2019, the CDSCO, with Union government approval, can issue orders specifying the name of the countries for considering waiver of local clinical trials for approval of new drugs.
  • The government has decided to waive the requirement for clinical trials in India if the drugs are approved in the U.S., the U.K., Japan, Australia, Canada, or the European Union.
  • A set of five categories for new drugs has been specified that will be considered for waiver in the Indian market. They include:
    • Drugs for rare diseases: These often lack sufficient patient populations for local trials. (https://compass.rauias.com/current-affairs/indias-fight-against-rare-diseases/) 
    • Gene and cellular therapy products: Cutting-edge treatments that require speedy approval.
    • New drugs for pandemic situations: To address urgent public health crises.
    • New drugs for special defence purposes: For military personnel.
    • Drugs with significant therapeutic advancements: To provide patients with better treatment options faster.

Significance:

  • Enhanced drug accessibility for patients and for research.
  • Drugs manufactured outside India will be more accessible and affordable in the local market. 
  • Address the critical and unmet medical needs and accelerate access to innovative therapies to the patients in India. 
  • By aligning with approvals from established regulatory bodies in other countries, India is moving towards global harmonisation in drug approval processes.

Central Drugs Standard Control Organisation (CDSCO): 

  • The Central Drugs Standard Control Organisation (CDSCO) is the Central Drug Authority in India. 
  • CDSCO is responsible for many functions under the Drugs and Cosmetics Act, including:
    • Approving new drugs and clinical trials
    • Setting standards for drugs
    • Controlling the quality of imported drugs
    • Coordinating the activities of state drug control organisations
    • Granting licences for certain specialised categories of critical drugs, such as blood and blood products, IV fluids, vaccines etc. 

GST on health insurance

Context: Opposition leaders demanding the withdrawal of 18% Goods and Services Tax (GST) on life insurance and health insurance premiums.

GST on health and life insurance premiums

  • GST replaced all indirect taxes like service tax and cess and is currently set at 18% for health and life insurance policies.
  • Prior to GST, life insurance premiums were subject to a 15% service tax, including Basic Service Tax, Swachh Bharat cess, and Krishi Kalyan cess. The increase to 18% has raised premium costs for policyholders.

Markets for life and health insurance in India:

  • General insurance industry: Collected Rs 1,09,000 crore in premiums under the health portfolio for fiscal 2023-24.
  • Life Insurance Companies: Mobilized Rs 3,77,960 crore in premiums in FY2024, with LIC accounting for a significant portion.
  • Regional contributions: Five states (Maharashtra, Karnataka, Tamil Nadu, Gujarat, and Delhi) contributed 64% of the total health insurance premiums.
  • Insurance penetration: Life insurance penetration decreased from 3.2% in 2021-22 to 3% in 2022-23, with non-life insurance remaining at 1%. Overall insurance penetration dropped to 4% from 4.2% during the same period.

Arguments for GST on health insurance:

  • Revenue generation: GST applies to all insurance policies as a service tax, generating significant revenue for the government, which can be used for public welfare and infrastructure development.
    • As government collected around Rs 21,000 crore in GST over the last 3 FYs, with an additional around Rs 3,000 crore from the reissuance of health policies.
  • Tax exemption: Insurance policies allow certain deductions while computing income tax under Sections 80C and 80D of the Income Tax Act, 1961.
    • Section 80C allows deductions of up to Rs 1.5 lakh on the total premium, including GST, while Section 80D provides additional deductions for medical riders with life insurance policies.
  • Simplification and uniformity: GST replaces multiple indirect taxes, simplifying the tax structure and providing uniformity across states, making it easier for insurers to comply with tax regulations.
  • Transparency: GST compliance often encourages digital record-keeping and transactions, lead to more transparency and efficiency in the insurance industry.
  • Constitutional framework: GST rates and exemptions are determined by the GST Council, which includes both central and state representatives. This ensures that decisions are made based on comprehensive inputs from various stakeholders.

Arguments against GST on health insurance: 

  • Increasing out-of-pocket expenses for healthcare: High GST rates on insurance, acts as a deterrent to buying policies, making it less affordable for individuals and families, especially for those already facing high medical costs and increasing out-of-pocket expenses for healthcare.
  • Premium increases: Significant increases in health insurance premiums have led to a decline in policy renewals and unable to achieve the goal of "Insurance for All by 2047."
  • Impact on vulnerable populations: Low-income groups and senior citizens may find it particularly challenging to afford insurance with the added GST, potentially leaving them without financial protection in medical emergencies.
  • Contradiction to public health goals: May contradict government efforts such as Swasth Bharat Viksit Bharat to promote healthcare access and financial protection for all citizens.
  • Potential for reduced coverage: Individuals may opt for lower coverage or higher deductibles to offset the increased costs due to GST, may undermine the effectiveness of their insurance in covering medical expenses.

Way forward: 

  • Parliamentary Standing Committee Recommendations: 
    • GST rates applicable to health insurance products, particularly retail policies for senior citizens and microinsurance policies (up to limits prescribed under PMJAY, presently Rs 5 lakh), and term policies may be reduced. 
    • It recommended that the Ayushman Bharat scheme can be expanded by allowing people who are not covered by the scheme to opt for it on a  paid basis to achieve public health goal.
  •  Sector-specific adjustments: Consideration of lower GST rates for specific categories such as retail policies for senior citizens, microinsurance policies, and health insurance could help in addressing affordability concerns.

Global scenario

  • In countries like Singapore and Hong Kong, there is no GST or VAT on insurance, making it more accessible to consumers.

Ayushman Arogya Mandir

Context: Ministry of Ayush is implementing operationalisation of Ayushman Arogya Mandir in the country to provide holistic health coverage based on Ayush to citizens of India.

About Ayushman Arogya Mandirs

  • Ayushman Arogya Mandirs will be created by transforming existing sub-health centres/Ayush dispensaries to Ayush Health & Wellness Centres to ensure universal access to expanded range of Primary Health Care services as appropriate to people's needs.
  • Implemented by: Ministry of Ayush as a sub-component of the centrally sponsored scheme, National Ayush Mission (NAM) which provides for operationalization of Ayush Heath & Wellness Centres (AHWC).
  • Under the National Ayush Mission, proposals are sent by State/UT Governments according to their State Annual Action Plans (SAAPs).
  • In total, 12,500 units of existing Ayush dispensaries and sub-health centres have been approved to be upgraded as Ayushman Arogya Mandir (Ayush) in the States/UTs.
  • According to reports from States/UTs, 12121 Ayushman Arogya Mandirs have been functional till date.

U-Win portal

Context: With the government planning to launch the U-Win digital vaccination registry on August 15, the Universal Immunization Programme (UIP) is set to be significantly strengthened. This portal replicates the Covid-19 vaccine management system, Co-WIN.

About U-Win portal

U-WIN - Apps on Google Play

  • It aims to maintain an electronic registry of routine immunisations.
  • Also aims to reduce zero-dose and left-out children through a name-based tracking mechanism and empower citizens with anytime, anywhere access to vaccination services, particularly benefiting migratory Populations.

A person sitting at a table with a doctor and a child

Description automatically generated

Target Population and Coverage

  • Captures every vaccination event for pregnant women and children aged 0-6 years under the Universal Immunization Programme (UIP).
  • Targets 2.9 crore pregnant women and 2.6 crore infants (0-1 years) annually.
  • Provides 11 vaccines against 12 vaccine-preventable diseases such as diphtheria, measles, rubella, and tetanus.
  • Conducts more than 1.2 crore vaccination sessions across the country annually.
  • Vaccination is free of cost at all Government Vaccination Centers.

Features of U-Win portal: 

  • The platform generates a uniform QR-based, digitally verifiable e-vaccination certificate, similar to Covid vaccination certificate, which can be accessed anytime by the citizens through a single click. It will enable the digitisation of session planning, and updating vaccination status on a real-time basis.
    • Vaccination records under UIP are being maintained manually as of now. So this will do away with the hassle of keeping a physical record.
  • Records pregnancy details and outcomes, newborn registration, and immunisation at birth.
  • Citizens can self-register for vaccinations via the U-WIN web portal or its Android mobile application. Allows selection of preferred vaccination centres and scheduling of appointments.
  • Facilitates on-spot registration during ongoing vaccination sessions.
  • Up to 10 people can be registered for vaccination using the same mobile number.
  • Sends automated SMS alerts for registration confirmations, administered doses, and upcoming dose reminders, ensuring timely and age-appropriate vaccinations.
  • Facilitates the creation of Ayushman Bharat Health Account (ABHA) IDs for comprehensive health record maintenance.

National Commission for Indian System of Medicine (NCISM)

Context: Recently, National Commission for Indian System of Medicine is celebrated its fourth foundation day.

The National Commission for Indian System of Medicine ensures availability of adequate and high-quality medical professionals of Indian System of Medicine (ISM); adoption of the latest medical research by medical professionals of Indian System of Medicine; and periodic assessment of ISM medical institutions.

About National Commission for Indian System of Medicine (NCISM)

  • NCISM is a statutory body constituted under the NCISM Act, 2020 to be created by Central Government by notification.
  • Indian System of Medicine to be regulated under the NCISM means Ashtang Ayurveda, Unani, Siddha and Sowa-Rigpa system of medicine
  • Composition of Commission: (i) Chairperson (ii) Fifteen ex-officio members (iii) 23 part-time members.
  • Qualification of Chairperson of NCISM: A person of outstanding ability, proven administrative capacity and integrity and possessing a post-graduate degree in any of the disciplines of Indian System of Medicine from a recognised University.

Functions of NCISM

  • Lay down policies of maintaining a high quality and high standards in education of Indian System of Medicine and make necessary regulations.
  • Lay down policies for regulating medical institutions, medical researches and medical professionals and make necessary regulations.
  • Assess the requirements in healthcare, including human resources for health and healthcare infrastructure and develop a roadmap for meeting such requirements.
  • Frame guidelines and policies by making such regulations as may be necessary for proper functioning of NCISM, Autonomous Boards and State Medical Councils of Indian System of Medicine.
  • Ensure coordination among Autonomous Boards.
  • Take such measures to ensure compliance by State Medical Councils of Indian System of Medicine of the guidelines framed and regulations for their effective functioning.
  • Exercise appellate jurisdiction with respect to decisions of Autonomous Boards.
  • Ensure observance of professional ethics in Medical profession and to promote ethical conduct during the provision of care by medical practitioners.
  • Frame guidelines for determination of fees and all other charges in respect of 50% of seats in private medical institutions and deemed to be universities which are governed by the Act.
  • Exercise such other functions as may be prescribed.